ANAVEX LIFE SCIENCES CORP. 8-K

What Happened
Anavex Life Sciences Corp. (AVXL) announced it received a delinquency notification from the Nasdaq Listing Qualifications Department on May 20, 2026, stating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it did not timely file its Quarterly Report on Form 10‑Q for the quarter ended March 31, 2026. The company filed an 8‑K and issued a press release on May 22, 2026, disclosing the notice. The company’s common stock continues to trade on the Nasdaq Global Select Market under the ticker AVXL.

Key Details

• Notice received: May 20, 2026; press release filed as Exhibit 99.1 on May 22, 2026.
• Noncompliance: Failure to timely file Form 10‑Q for quarter ended March 31, 2026 (Nasdaq Listing Rule 5250(c)(1)).
• Compliance deadline: Company must submit a plan to Nasdaq by July 20, 2026.
• Possible outcomes: If Nasdaq accepts the plan, the exchange may grant up to 180 days from the Form 10‑Q due date (through November 16, 2026) to regain compliance; if not accepted, the company can appeal to a Nasdaq Hearings Panel.
• Company action: Anavex says it is working to complete and file the Form 10‑Q and will submit a compliance plan.

Why It Matters
For investors, this is a governance and reporting risk signal: the company is currently delinquent in required SEC filings, which can lead to accelerated regulatory scrutiny or potential delisting if not resolved. However, there is no immediate trading suspension—the stock remains listed and tradable while Anavex seeks to regain compliance. Monitor upcoming filings (the Form 10‑Q and any Nasdaq correspondence) and the company’s July 20, 2026 compliance-plan submission for developments that could affect the stock’s listing status.